Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis

Journal of Infection and Chemotherapy

Volumn 19, Issue 4, 2013, Pages 683-690

  Nanjo, Yuta ^a,b   Ishii, Yoshikazu ^a   Kimura, Soichiro ^a   Fukami, Toshiro ^c   Mizoguchi, Masahiro ^c   Suzuki, Toyofumi ^c   Tomono, Kazuo ^c   Akasaka, Yoshikiyo ^a   Ishii, Toshiharu ^a   Takahashi, Kazuhisa ^b   Tateda, Kazuhiro ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Colistin; Endotoxin; PLGA microsphere; Toxicity

Indexed keywords

COLISTIN; ENDOTOXIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROSPHERE; POLYGLACTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG OVERDOSE; HISTOPATHOLOGY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; SEPSIS; SEPTIC SHOCK; SLOW RELEASE FORMULATION; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; ENDOTOXINS; INJECTIONS, SUBCUTANEOUS; KIDNEY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C3H; MICROSPHERES; SHOCK, SEPTIC;

EID: 84882269964     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0544-y     Document Type: Article

References (39)

1. Vincent JL. Clinical sepsis and septic shock - definition, diagnosis and management principles. Langenbecks Arch Surg. 2008;393:817-24.
2. Alkharfy KM, Al-Daghri NM, Al-Attas OS, Alokail MS. The protective effect of thymoquinone against sepsis syndrome morbidity and mortality in mice. Int Immunopharmacol. 2011;11:250-4.
3. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001;29:S109-16.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
5. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695-701.
6. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.
7. Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide- induced lethality and cytokine production in aged mice. Infect Immun. 1996;64:769-74.
8. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003;7:108-14.
9. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis. 2011;11:65-71.
10. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457-69.
11. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445-52.
12. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527-34.
13. Anspach FB. Endotoxin removal by affinity sorbents. J Biochem Biophys Methods. 2001;49:665-81.
14. From AH, Fong JS, Good RA. Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun. 1979;23:660-4.
15. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967;93:1463-4.
16. Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol. 1966;92:815-9.
17. Hughes B, Madan BR, Parratt JR. Sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol. 1981;74:701-7.
18. Hanasawa K, Tani T, Oka T, Yoshioka T, Endo Y, Horisawa M, et al. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. 1984. Ther Apher. 2000;4:142-5.
19. Bannatyne RM, Cheung R. Protective effect of polymyxin B sulfate in experimental enterobacterial infection in mice. Can J Microbiol. 1979;25:995-8.
20. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41:645-54.
21. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811-21.
22. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53:837-40.
23. Institute CaLS. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. Wayne: CLSI; 2011 (M100-S21).
24. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo). 1988;36:1095-103.
25. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167-75.
26. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534-42.
27. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51:446-52.
28. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267-93.
29. Van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, et al. Clinical significance of translocation. Gut. 1994;35:S28-34.
30. Buttenschoen K, Radermacher P, Bracht H. Endotoxin elimination in sepsis: physiology and therapeutic application. Langenbecks Arch Surg. 2010;395:597-605.
31. Zhong M, Kadota Y, Shimizu Y, Gohda E. Induction of cytolytic activity and interferon-gamma production in murine natural killer cells by polymyxins B and E. Int Immunopharmacol. 2008;8:508-13.
32. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
33. Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2011;37:141-6.
34. Mendes CA, Burdmann EA. Polymyxins - review with emphasis on nephrotoxicity. Rev Assoc Med Bras. 2009;55:752-9.
35. Moyer JH, Mills LC, Yow EM. Toxicity of polymyxin B. I. Animal studies with particular reference to evaluation of renal function. AMA Arch Intern Med. 1953;92:238-47.
36. Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13:11-32.
37. McMillan FH, Pattison IC. Sodium colistimethate. I. Dissociations of aminomethanesulfonates in aqueous solution. J Pharm Sci. 1969;58:730-7.
38. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781-5.
39. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003;47:1364-70.